Zejula (niraparib) is the first and only once-daily PARP inhibitor FDA-approved as a first-line monotherapy maintenance treatment for women with advanced ovarian cancer regardless of biomarker status
GlaxoSmithKline plc today announced the U.S. FDA approved the company’s supplemental New Drug Application (sNDA) of Zejula (niraparib).
